Recent brand acquisition will help boost domestic sales
CPL Biologicals, which has developed the vaccine, is a JV between Cadila and US-based Novavax
Analysts believe growth worries for the base business are behind it and expect H2 to be much better
The scrip had also outperformed the market in past one quarter, rising 18.84% as against Sensex's 0.26% decline
The stock dipped 8% to Rs 374 after the company reported 29% YoY drop in its consolidated net profit at Rs 338 crore in Q2FY17.
The EIR report is given to an establishment after the completion of an inspection by the USFDA
The stock moved higher by 4% to Rs 391 on the BSE.
Last month, the firm received EIR for its manufacturing facility in Moraiya
Solving problems relating to its Moraiya unit will be key
At NSE, shares of the company surged 9.21 per cent to Rs 379.75
The stock surged nearly 10% to Rs 380 on the BSE after the management guided for 12-15 launches over FY17.
Shares of the company closed at Rs 347 on BSE, down 0.22% from the previous close
Resolution of US FDA issues of 2014 is positive
The stock moved higher by 5% to Rs 375 on the BSE.
The pharma major is also planning to enhance its share in US generics market by launching complex, oral solids and formulations
During 2015-16, the company's business in the US remained the largest contributor to the consolidated revenue, which crossed $600 million in sales for the first time
The company has received Establishment Inspection Report which indicates closure of inspection points of initial review
Alembic Pharma and Cadila Healthcare were up 4% each as compared to 0.18% fall in Sensex at 01:38 PM.
With little clarity on timing of Moraiya plant clearance by FDA, gains from product launches might get delayed
The company has received final approval from the USFDA for Glyburide and Metformin Hcl tablets USP